Update in pulmonary hypertension 2008

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 8, 2009, Pages 650-656

  Humbert, Marc ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMINOREX; ANOREXIGENIC AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CYCLOPHOSPHAMIDE; FENFLURAMINE; GLUCOCORTICOID; IMATINIB; PLACEBO; PROSTACYCLIN; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENE MUTATION; HEREDITARY HYPERTENSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MIXED CONNECTIVE TISSUE DISEASE; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; SCHISTOSOMIASIS; SICKLE CELL ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; HYPERTENSION, PULMONARY;

EID: 65249147738     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200901-0136UP     Document Type: Review

References (89)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-1538.
3. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-1383.
4. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF- beta family. J Med Genet 2000;37:741-745.
5. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M, Cuervo N, Moore KJ, Hodge SE, Knowles JA, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002;20:518-523.
6. Souza R, Humbert M, Sztrymf B, Jaïs X, Yaïci A, Le Pavec J, Parent F, Hervé P, Soubrier F, Sitbon O, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008;31:343-348.
7. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-3050.
8. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-157.
9. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jais X, Yaici A, Humbert M, Simonneau G, et al. Portopulmonary yyper-tension: survival and prognostic factors. Am J Respir Crit Care Med 2008;178:637-643.
10. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Lüthy R. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-995.
11. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-1439.
12. Lederman MM, Sereni D, Simonneau G, Voelkel NF. Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS 2008;22:S1-S6.
13. Dimopoulos K, Giannakoulas G, Wort SJ, Gatzoulis MA. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 2008;23:545-554.
14. Rich S, Danzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223.
15. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-349.
16. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
17. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
18. Peacock A, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension in Scotland. Eur Respir J 2007;30:104-109.
19. Thenappan T, Shah SJ, Rich S. Gomberg-Maitland. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110.
20. Tueller C, Stricker H, Soccal P, Tamm M, Aubert JD, Maggiorini M, Zwahlen M, Nicod L; Swiss Society for Pulmonary Hypertension. Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly 2008;138:379-384.
21. Fischler M, Speich R, Dorschner L, Nicod L, Domenighetti G, Tamm M, Rochat T, Aubert JD, Ulrich S; Swiss Society for Pulmonary Hypertension. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly 2008;138:371-378.
22. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985;27:160-171.
23. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-616.
24. Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984;129:194-197.
25. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995;152:93-97.
26. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA III, Newman JH, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997;15:277-280.
27. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler R, Seeger W, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-132.
28. Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM, Hedges LK, Stanton KC, Wheeler LA, Phillips JA III, Loyd JE, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:590-598.
29. Aldred MA, Machado RD, James V, Morrell NW, Trembath RC. Characterization of the BMPR2 5'-untranslated region and novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007;176:819-824.
30. Rosenzweig EB, Morse JH, Knowles JA, Chada KK, Khan AM, Roberts KE, McElroy JJ, Juskiw NK, Mallory NC, Rich S, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008;27:668-674.
31. Meyrick BO, Friedman DB, Billheimer DD, Cogan JD, Prince MA, Philips JA III, Loyd JE. Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:99-107.
32. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.
33. Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, Humbert M. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59:446-448.
34. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-944.
35. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, Simonneau G, Humbert M. Management of lupus and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2008;58:521-531.
36. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007;86:299-315.
37. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271.
38. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141.
39. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary arterial hypertension in the current anti-retroviral therapy era. Am J Respir Crit Care Med 2008;177:108-113.
40. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008;22:S35-S40.
41. Degano B, Yaïci A, Le Pavec J, Savale L, Jaïs X, Camara B, Humbert M, Simonneau G, Sitbon O. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-98.
42. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef- infected macaques. Am J Respir Crit Care Med 2006;174:437-445.
43. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008;48:196-203.
44. Butros G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation 2008;118:1758-1766.
45. Lapa M, Dias B, Jardim C, Fernandes CJC, Dourado PMM, Figueiredo M, Farias A, Tsuitsui J, Terra-Filho M, Humbert M, et al. Cardio-pulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009; (in press).
46. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008;359:2254-2265.
47. Mekontso-Dessap A, Leon R, Habibi A, Nzouakou R, Roudot-Thoraval F, Adnot S, Godeau B, Galacteros F, Brun-Buisson C, Brochard L, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2008;177:646-653.
48. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, et al. Pulmonary hypertension as a risk of death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
49. Anthi A, Machado RF, Jison ML, Taveira-DaSilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007;175:1272-1279.
50. McLaughlin VV, Channick R. Sickle cell disease-associated pulmonary hypertension: a coat of many colors. Am J Respir Crit Care Med 2007;175:1218-1219.
51. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, Tcherakian C, Rabiller A, Haque R, Sitbon O, JaiisX,et al. Pulmonary veno- occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87:220-233.
52. Montani D, Price LC, Dorfmuller P, Achouh L, JaiisX, Yaiici A, Sitbon O, Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease. Eur Respir J 2009;33:189-200.
53. Rabiller A, Jais X, Hamid A, Resten A, Parent F, Haque R, Capron F, Sitbon O, Simonneau G, Humbert M. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006;27:108-113.
54. Creagh-Brown BC, Nicholson AG, Showkathali R, Gibbs JSR, Howard LSGE. Pulmonary veno-occlusive disease presenting with recurrent pulmonary edema and the use of nitric oxide to predict response to sildenafil. Thorax 2008;63:933-934.
55. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno- occlusive disease. Eur Respir J 2008;32:232-235.
56. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, et al. Platelet derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-88.
57. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk K, Pruszczyk P, Szturmowicz M. Serum N-terminal brain natriuretic peptide in patients with pulmonary hypertension. Chest 2006;129:1313-1321.
58. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, Girgis RE, Hassoun PM. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1364-1369.
59. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:536-543.
60. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle level predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1265-1275.
61. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC. Growth differentiation factor-15 for prognosis assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008;178:534-541.
62. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, Olsson K, Wilkins MR, Gibbs JSR, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:534-541.
63. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. Asymmetrical dimethylarginine in idio- pathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-1418.
64. Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R, Jakowitsch J, Klepetko W, Kneussel MP, Wolzt M, et al. Asymetric dimethylarginine is increased in chronic thrombo-embolic pulmonary hypertension. Am J Respir Crit Care Med 2007;176:1154-1160.
65. Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaici A, Hotellier F, Simmoneau G, Guillevin L, et al. Identification of target antigens of anti-fibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1128-1134.
66. Galie N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;371:2093-2100.
67. Dhaun N, Webb DJ. Endothelin receptor antagonism: the future is bright. Lancet 2008;371:2061-2062.
68. Galie N, Olschewski H, Oudiz R, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Toecker EB, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019.
69. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 2008;149:521-530.
70. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboem-bolic pulmonary hypertension. Circulation 2006;113:2011-2020.
71. Toshner M, Suntharalingam J, Goldsmith K, Niggebrugge A, Pepke-Zaba J, Morrell NW, Tsui S, Flowers J, Jenkins D. Current differences in referral patterns for pulmonary endarterectomy in the UK. Eur Respir J 2008;32:660-663.
72. Bonderman D, Wilkens H, Wakounig S, Schaifers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:325-331.
73. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Goldsmith K, Coghlan JG, Pepke-Zaba J. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:332-338.
74. Corsico AG, D'Armini AM, Cerveri I, Klersy C, Ansaldo E, Niniano R, Gatto E, Monterosso C, Morsolini M, Nocolardi S, et al. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med 2008;178:419-424.
75. Condliffe R, Kiely DG, Gibbs JSR, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1122-1127.
76. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, Klepetko W, Kneussl M, Lang IM. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007;115:2153-2158.
77. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30:922-927.
78. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, et al. Bosentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2008;52:2127-2134.
79. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med 2008;177:574-579.
80. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
81. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194.
82. Thabut G, Dauriat G, Stern JB, Logeart D, Lévy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531-1536.
83. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007;115:1132-1146.
84. Richalet JP, Rivera-Ch M, Maignan M, Privat C, Pham I, Macalarpu JL, Petitjean 0, Leon-Velarde F. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med 2008;177:1370-1376.
85. Maignan M, Rivera-Ch M, Privat C, Leon-Valverde F, Richalet JP, Pham I. Pulmonary pressure and cardiac function in chronic mountain sickness. Chest 2009;135:499-504.
86. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-1495.
87. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-2379.
88. Rai PR, Cool CD, King JAC, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterialhypertension. Am J Respir Crit Care Med 2008;178:558-564.
89. Humbert M, Hoeper MM. Severe pulmonary arterial hypertension: a forme fuste of cancer? Am J Respir Crit Care Med 2008;178:551-552.